Search Results | NIH

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Search Results 2481 – 2500 of 3236

Ritonavir (Norvir, RTV)

https://clinicalinfo.hiv.gov/guidelines/perinatal/safety-toxicity-arv-agents-pharmacoenhancers-ritonavir-norvir

Pregnancy and Postpartum HIV Testing and Identification of Perinatal and Postnatal HIV Exposure

https://clinicalinfo.hiv.gov/guidelines/perinatal/maternal-hiv-testing-identification-exposure

https://clinicalinfo.hiv.gov/guidelines/perinatal/archived-drugs-overview

https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/indinavir

Laboratory Testing for Initial Assessment and Monitoring of People With HIV

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/tests-initial-assessment-follow-up

Special Populations

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/special-populations

Special Populations: Substance Use Disorders and HIV

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/special-populations-substance-use-disorders

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/tables

Table 5. Significant Drug Interactions for Drugs Used to Treat or Prevent Opportunistic Infections

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/table-5-significant-drug

Laboratory Testing: Plasma HIV-1 RNA (Viral Load) and CD4 Count Monitoring

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/plasma-hiv-1-rna-cd4-monitoring

https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/overview

Long-Term Follow-Up of Infants Exposed to Antiretroviral Drugs

https://clinicalinfo.hiv.gov/guidelines/perinatal/management-infants-long-term-follow-up-exposed-arv-drugs

Financial Disclosure

https://clinicalinfo.hiv.gov/guidelines/perinatal/financial-disclosure

Protease Inhibitors

https://clinicalinfo.hiv.gov/guidelines/perinatal-hiv-clinical-guidelines/protease-inhibitors

Lopinavir/Ritonavir (Kaletra, LPV/r)

https://clinicalinfo.hiv.gov/guidelines/perinatal/safety-toxicity-arv-agents-protease-inhibitors-lopinavir-ritonavir-kaletra

Darunavir (Prezista, DRV)

https://clinicalinfo.hiv.gov/guidelines/perinatal/safety-toxicity-arv-agents-protease-inhibitors-darunavir-prezista

Initial Evaluation and Continued Monitoring of HIV During Pregnancy

https://clinicalinfo.hiv.gov/guidelines/perinatal/antepartum-care-initial-evaluation-monitoring-hiv-assessments-during-pregnancy

Appendix C: Antiretroviral Counseling Guide for Health Care Providers

https://clinicalinfo.hiv.gov/guidelines/perinatal/arv-counseling-guide

Hepatitis C Virus Infection

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/hepatitis-c-virus-infection

Intrapartum HIV Care

https://clinicalinfo.hiv.gov/guidelines/perinatal/intrapartum-care